Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Novavax, Inc.

Market Cap 1.51B 1.31B 1.2B 1.13B 2.12B 143B 2.14B 14.2B 5.53B 70.12B 5.68B 5.56B 243B P/E Ratio 2026 *
-19.5x
P/E Ratio 2027 * -36.2x
Enterprise Value 1.73B 1.49B 1.38B 1.29B 2.43B 164B 2.45B 16.26B 6.33B 80.26B 6.51B 6.37B 278B EV / Sales 2026 *
4.23x
EV / Sales 2027 * 7.03x
Free-Float
93.1%
Yield 2026 *
-
Yield 2027 * -
1 day-1.80%
1 week+1.25%
Current month-12.47%
1 month+3.46%
3 months-9.27%
6 months+44.52%
Current year+39.04%
1 week 7.37
Extreme 7.37
8.07
1 month 7.35
Extreme 7.35
9.81
Current year 5.74
Extreme 5.74
9.88
1 year 5.31
Extreme 5.309
9.88
3 years 4.71
Extreme 4.706
13.35
5 years 4.71
Extreme 4.706
13.35
10 years 4.71
Extreme 4.706
13.35
Manager TitleAgeSince
Chief Executive Officer 59 2023-01-22
Director of Finance/CFO 60 2021-08-15
Chief Operating Officer - 2020-11-30
Director TitleAgeSince
Director/Board Member 73 2010-08-05
Director/Board Member 66 2018-10-31
Director/Board Member 60 2020-06-15
Change 5-day change 1-year change 3-year change Capi.($)
-1.80%+1.25% - - 1.51B
-0.12%+1.04%-13.08%-12.43% 43.58B
+0.43%+5.28%+295.88%+539.48% 34.03B
+5.77%-3.77%+12.54%-17.04% 29.77B
+13.09%-1.38%+0.02%+32.09% 29.82B
-0.29%+9.47%+13.95%+21.93% 25.42B
-7.56%+8.68% - - 13.87B
-2.75%-0.79%+53.86%+108.77% 13.35B
-1.04%-3.33%+3.98%+3.91% 12.85B
+4.27%-1.76%+107.90%+78.61% 12.22B
Average -0.40%+2.03%+59.38%+94.41% 23.88B
Weighted average by Cap. -0.41%+2.02%+61.26%+105.87%

Financials

2026 *2027 *
Net sales 410M 353M 325M 305M 574M 38.76B 580M 3.84B 1.5B 18.98B 1.54B 1.51B 65.78B 258M 223M 205M 193M 362M 24.44B 365M 2.42B 944M 11.97B 970M 949M 41.47B
Net income -79.31M -68.35M -62.94M -59.09M -111M -7.5B -112M -744M -290M -3.67B -298M -291M -12.72B -43.22M -37.25M -34.3M -32.2M -60.46M -4.09B -61.1M -405M -158M -2B -162M -159M -6.93B
Net Debt 219M 189M 174M 163M 306M 20.71B 310M 2.05B 800M 10.14B 822M 804M 35.14B 303M 261M 241M 226M 424M 28.67B 429M 2.84B 1.11B 14.04B 1.14B 1.11B 48.65B
Logo Novavax, Inc.
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Employees
749
Date Price Change Volume
26-06-14 8.070 +2.93% 47
26-06-16 7.740 -4.09% 3
26-06-15 8.070 +2.93% 47
26-06-12 7.840 +3.29% 38
26-06-11 7.590 +2.71% 50
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
9.210USD
Average target price
14.11USD
Spread / Average Target
+53.24%

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!